Modular Medical (MODD) Financials

Modular Medical (NASDAQ: MODD) continues to look like a development-stage medical device company that is still far from profitability, but it has also shown a meaningful ability to raise capital and maintain a cash balance. Over the last four years, the biggest story is not revenue growth — revenue remains essentially nonexistent in the data provided — but rather the company’s persistent operating losses, repeated share issuance, and ongoing investment in R&D and manufacturing assets.

For retail investors, the key takeaway is that MODD is still in a classic pre-commercial or early-commercial burn phase. That means the stock’s future will likely depend on product adoption, regulatory/commercial progress, and whether management can turn heavy spending into future revenue before dilution becomes too severe.

• Cash improved sequentially in Q4 2026, with cash and equivalents rising from $2.9 million in Q3 2026 to a net increase in cash of $4.0 million for the quarter, helped by $10.8 million of common equity issuance.
• Balance sheet equity was still positive in the latest quarter, with total equity of $5.9 million at Q3 2026, indicating the company was not in immediate negative equity territory at that point.
• Operating losses improved versus prior quarters in Q4 2026, as net loss narrowed to $6.4 million from $7.4 million in Q3 2026.
• Operating cash burn also improved in Q4 2026, with operating cash outflow of $5.8 million compared with $7.2 million in Q3 2026.
• Capital spending has generally been lower than operating losses, suggesting management is not overspending on fixed assets relative to the size of the company, even though it continues to invest in plant and equipment.
• Revenue remains at $0 across the periods shown, so current results are driven entirely by expenses and financing, not sales.
• R&D remains elevated, which is typical for a medtech company, but it also means the company is still consuming cash to develop its product platform.
• Weighted average shares outstanding have increased sharply over time, reflecting substantial dilution as the company funds operations.
• Other income/expense is inconsistent but relatively small compared with the company’s operating losses, so it is not a major driver of results.
• MODD is still deeply unprofitable, with Q4 2026 net loss of $6.4 million and no revenue to offset expenses.
• Operating cash flow remains negative every quarter provided, indicating the business is not self-funding.
• The company relies heavily on equity issuance to survive, including $11.4 million in Q4 2025, $6.0 million in Q3 2026, and $10.8 million in Q4 2026.
• Share dilution is severe, with weighted average basic shares rising from roughly 22.4 million in Q2 2024 to 65.9 million in Q3 2026, which can pressure per-share value even if the business improves.
• Cash has been volatile and generally declining without financing support, as operating losses consistently outpaced internally generated cash.
• Accumulated losses are large, shown by the deeply negative retained earnings balance across periods, underscoring the long path to profitability.

Overall, Modular Medical appears to be in a high-risk, high-dilution development phase. The latest quarter shows some moderation in losses, but the company still has to prove it can generate revenue and reduce dependence on equity financing. Until that happens, investors should expect continued volatility and a strong reliance on future capital raises.